抗体药物-话题@MedSci

#抗体药物#

61篇内容 | 2110人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2016176, encodeId=559320161e6fa, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Sci Adv：程柯团队带来抗体药物靶向受损心脏新方法, objectType=article, longId=187650, objectId=405818e650e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=405818e650e0, replyNumber=0, likeNumber=66, createdTime=2020-06-04, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=405818e650e0, moduleTitle=Sci Adv：程柯团队带来抗体药物靶向受损心脏新方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=405818e650e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016182, encodeId=87b52016182b5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=礼来启动新冠病毒COVID-19抗体药物的全球临床试验, objectType=article, longId=195466, objectId=861d19546646, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861d19546646, replyNumber=0, likeNumber=70, createdTime=2020-07-09, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861d19546646, moduleTitle=礼来启动新冠病毒COVID-19抗体药物的全球临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861d19546646)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016189, encodeId=54c72016189f7, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤, objectType=article, longId=199756, objectId=08d0199e56b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08d0199e56b3, replyNumber=0, likeNumber=73, createdTime=2020-12-02, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08d0199e56b3, moduleTitle=靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08d0199e56b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016188, encodeId=d5d220161884f, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤, objectType=article, longId=198901, objectId=876c19890119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=876c19890119, replyNumber=0, likeNumber=109, createdTime=2020-12-17, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=876c19890119, moduleTitle=**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=876c19890119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016171, encodeId=0a6c20161e172, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=盘点丨2019年欧美首批的5款抗体药物, objectType=article, longId=184891, objectId=080b1848915c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=080b1848915c, replyNumber=0, likeNumber=59, createdTime=2020-10-22, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=080b1848915c, moduleTitle=盘点丨2019年欧美首批的5款抗体药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=080b1848915c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016177, encodeId=02eb20161e749, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代, objectType=article, longId=189508, objectId=d6db18950878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6db18950878, replyNumber=0, likeNumber=68, createdTime=2020-10-20, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6db18950878, moduleTitle=百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6db18950878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016169, encodeId=bcc4201616947, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=抗体药物偶联物治疗肺癌：U3-1402和DS-1062的临床结果更新将在2019年世界肺癌大会上发表, objectType=article, longId=178109, objectId=29b21e810910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29b21e810910, replyNumber=0, likeNumber=77, createdTime=2019-10-16, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29b21e810910, moduleTitle=抗体药物偶联物治疗肺癌：U3-1402和DS-1062的临床结果更新将在2019年世界肺癌大会上发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29b21e810910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016179, encodeId=53a620161e9c7, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, objectType=article, longId=194130, objectId=0b9d19413073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9d19413073, replyNumber=0, likeNumber=103, createdTime=2020-10-01, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9d19413073, moduleTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9d19413073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016178, encodeId=60d420161e8cd, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌, objectType=article, longId=190853, objectId=1643190853f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1643190853f0, replyNumber=0, likeNumber=79, createdTime=2020-07-19, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1643190853f0, moduleTitle=抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1643190853f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016175, encodeId=1db020161e57d, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, objectType=article, longId=186821, objectId=44e318682186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44e318682186, replyNumber=0, likeNumber=64, createdTime=2021-01-02, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44e318682186, moduleTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44e318682186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016172, encodeId=452320161e27d, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=抗体药物偶联物OBI-999治疗胰腺癌获得FDA孤儿药物认定, objectType=article, longId=185335, objectId=6cc718533567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cc718533567, replyNumber=0, likeNumber=58, createdTime=2020-10-27, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cc718533567, moduleTitle=抗体药物偶联物OBI-999治疗胰腺癌获得FDA孤儿药物认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cc718533567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016174, encodeId=b23d20161e459, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=展望2020：抗体药物, objectType=article, longId=185531, objectId=1ff7185531c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ff7185531c0, replyNumber=0, likeNumber=60, createdTime=2020-08-27, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ff7185531c0, moduleTitle=展望2020：抗体药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ff7185531c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016167, encodeId=69ec201616ec5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=**纳米抗体药物Cablivi®, objectType=article, longId=165825, objectId=3f4e165825ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4e165825ab, replyNumber=0, likeNumber=72, createdTime=2019-09-29, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4e165825ab, moduleTitle=**纳米抗体药物Cablivi®, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f4e165825ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016173, encodeId=dde120161e3c0, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了, objectType=article, longId=185383, objectId=415318538314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=415318538314, replyNumber=0, likeNumber=73, createdTime=2020-07-09, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=415318538314, moduleTitle=百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=415318538314)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016166, encodeId=742d201616625, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=LEO Pharma和Elektrofi合作改善抗体药物的输送，用于治疗皮肤病, objectType=article, longId=164067, objectId=60c816406e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60c816406e5c, replyNumber=0, likeNumber=71, createdTime=2019-05-19, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60c816406e5c, moduleTitle=LEO Pharma和Elektrofi合作改善抗体药物的输送，用于治疗皮肤病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60c816406e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016170, encodeId=0aef20161e011, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=2019年国内抗体药物市场和临床研究现状, objectType=article, longId=178265, objectId=02eb1e82652b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02eb1e82652b, replyNumber=0, likeNumber=59, createdTime=2020-01-28, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02eb1e82652b, moduleTitle=2019年国内抗体药物市场和临床研究现状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02eb1e82652b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016165, encodeId=c6f7201616570, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=国产PD-1抗体药物——君实生物特瑞普利单抗获批！, objectType=article, longId=156025, objectId=fb2f1560250e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb2f1560250e, replyNumber=0, likeNumber=73, createdTime=2019-10-12, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb2f1560250e, moduleTitle=国产PD-1抗体药物——君实生物特瑞普利单抗获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb2f1560250e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016163, encodeId=c06a2016163eb, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Cell Rep:免疫激活型抗体药物作用机制研究获进展, objectType=article, longId=152256, objectId=4c65152256f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c65152256f7, replyNumber=0, likeNumber=73, createdTime=2018-11-27, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c65152256f7, moduleTitle=Cell Rep:免疫激活型抗体药物作用机制研究获进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c65152256f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016168, encodeId=afd72016168b8, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, objectType=article, longId=165882, objectId=9c0116588208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0116588208, replyNumber=0, likeNumber=50, createdTime=2020-01-21, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0116588208, moduleTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0116588208)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016164, encodeId=6cc720161640b, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=第二代PD-1抗体药物M7824寻求国内上市，肿瘤免疫治疗一片红海, objectType=article, longId=153783, objectId=db76153e83a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db76153e83a2, replyNumber=0, likeNumber=63, createdTime=2019-04-25, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db76153e83a2, moduleTitle=第二代PD-1抗体药物M7824寻求国内上市，肿瘤免疫治疗一片红海, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db76153e83a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抗体药物

2020-05-29

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Sci Adv：程柯团队带来抗体药物靶向受损心脏新方法

2020-06-04

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

礼来启动新冠病毒COVID-19抗体药物的全球临床试验

2020-07-09

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

靶向CD79a的抗体药物偶联物Polivy，获NICE推荐治疗复发或难治性大B细胞淋巴瘤

2020-12-02

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤

2020-12-17

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

盘点丨2019年欧美首批的5款抗体药物

2020-10-22

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代

2020-10-20

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

抗体药物偶联物治疗肺癌：U3-1402和DS-1062的临床结果更新将在2019年世界肺癌大会上发表

2019-10-16

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌

2020-10-01

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌

2020-07-19

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点

2021-01-02

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

抗体药物偶联物OBI-999治疗胰腺癌获得FDA孤儿药物认定

2020-10-27

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

展望2020：抗体药物

2020-08-27

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

**纳米抗体药物Cablivi®

2019-09-29

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了

2020-07-09

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

LEO Pharma和Elektrofi合作改善抗体药物的输送，用于治疗皮肤病

2019-05-19

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

2019年国内抗体药物市场和临床研究现状

2020-01-28

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

国产PD-1抗体药物——君实生物特瑞普利单抗获批！

2019-10-12

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Cell Rep:免疫激活型抗体药物作用机制研究获进展

2018-11-27

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景

2020-01-21

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

第二代PD-1抗体药物M7824寻求国内上市，肿瘤免疫治疗一片红海

2019-04-25

科室
- - 订阅+
  - 更多科室
工具
服务